FRAX597, a PAK1 inhibitor, synergises with gemcitabine in the reduction of pancreatic cancer growth

The effect of FRAX597, either alone or in combination with gemcitabine, on the human pancreatic cancer cell lines, PANC-1, MiaPaCa-2, and BxPC-3, and on the murine pancreatic cancer cell lines, Pan02 and LM-P, was examined in vitro.

Saved in:
Bibliographic Details
Published in:Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2015-06, Vol.15 (3), p.S36-S36
Main Authors: Yeo, Dannel, He, Hong, Baldwin, Graham, Nikfarjam, Mehrdad
Format: Article
Language:English
Subjects:
Endocrinology & Metabolism
Gastroenterology and Hepatology
Pancreatic cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effect of FRAX597, either alone or in combination with gemcitabine, on the human pancreatic cancer cell lines, PANC-1, MiaPaCa-2, and BxPC-3, and on the murine pancreatic cancer cell lines, Pan02 and LM-P, was examined in vitro.
ISSN:1424-3903
1424-3911
DOI:10.1016/j.pan.2015.05.155